CompletedPhase 2NCT01913652
Ph II Cabazitaxel DD Liposarcoma
Studying Dedifferentiated liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Larry Hayward, MDWestern General Hospital, Edinburgh, United Kingdom
- Intervention
- Cabazitaxel(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2014 – 2020
Study locations (11)
- Universitair Ziekenhuis Antwerpen (117), Antwerp, Belgium
- Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet (101), Brussels, Belgium
- CHU de Dijon - Centre Georges-Francois-Leclerc (229), Dijon, France
- Centre Leon Berard (227), Lyon, France
- Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone (287), Marseille, France
- Fondazione IRCCS Istituto Nazionale dei Tumori (704), Milan, Italy
- Istituto Oncologico Veneto IRCCS - Ospedale Busonera (3908), Padua, Italy
- Clatterbridge Centre for Oncology NHS Trust - Clatterbridge Cancer Centre NHS Foundation Trust (659), Bebington, United Kingdom
- Western General Hospital, Edinburgh, United Kingdom
- Royal Marsden Hospital - Chelsea, London (613), London, United Kingdom
- The Christie NHS Foundation Trust (610), Manchester, United Kingdom
Collaborators
Sanofi
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01913652 on ClinicalTrials.govOther trials for Dedifferentiated liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06498648Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06422806Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06389799A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)Lund University Hospital
- RECRUITINGPHASE1NCT05711615Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT05694871Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated LiposarcomaAlliance for Clinical Trials in Oncology
- ACTIVE NOT RECRUITINGPHASE2NCT05886634A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated LiposarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT05607095A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated LiposarcomaMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE3NCT04967521SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated LiposarcomaSarcoma Alliance for Research through Collaboration